These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

640 related items for PubMed ID: 16144781

  • 1. Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable.
    Parellada E, Andrezina R, Milanova V, Glue P, Masiak M, Turner MS, Medori R, Gaebel W.
    J Psychopharmacol; 2005 Sep; 19(5 Suppl):5-14. PubMed ID: 16144781
    [Abstract] [Full Text] [Related]

  • 2. Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia.
    Marinis TD, Saleem PT, Glue P, Arnoldussen WJ, Teijeiro R, Lex A, Latif MA, Medori R.
    Pharmacopsychiatry; 2007 Nov; 40(6):257-63. PubMed ID: 18030649
    [Abstract] [Full Text] [Related]

  • 3. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J.
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [Abstract] [Full Text] [Related]

  • 4. Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder.
    Rossi A, Bagalà A, Del Curatolo V, Scapati F, Bernareggi MM, Giustra MG, Risperidone Long-Acting Trial Investigators (R-LAI).
    Hum Psychopharmacol; 2009 Oct; 24(7):574-83. PubMed ID: 19790173
    [Abstract] [Full Text] [Related]

  • 5. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
    Lindenmayer JP, Eerdekens E, Berry SA, Eerdekens M.
    J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
    [Abstract] [Full Text] [Related]

  • 6. Long-acting risperidone in stable patients with schizoaffective disorder.
    Mohl A, Westlye K, Opjordsmoen S, Lex A, Schreiner A, Benoit M, Bräunig P, Medori R.
    J Psychopharmacol; 2005 Sep; 19(5 Suppl):22-31. PubMed ID: 16144783
    [Abstract] [Full Text] [Related]

  • 7. Long-acting risperidone improves negative symptoms in stable psychotic patients.
    Curtis VA, Katsafouros K, Möller HJ, Medori R, Sacchetti E.
    J Psychopharmacol; 2008 May; 22(3):254-61. PubMed ID: 18308804
    [Abstract] [Full Text] [Related]

  • 8. Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: reasons for switching and safety.
    Hawley C, Turner M, Latif MA, Curtis V, Saleem PT, Wilton K.
    Hum Psychopharmacol; 2010 Jan; 25(1):37-46. PubMed ID: 20041474
    [Abstract] [Full Text] [Related]

  • 9. Long-term safety and efficacy of long-acting risperidone in elderly psychotic patients.
    Kissling W, Glue P, Medori R, Simpson S.
    Hum Psychopharmacol; 2007 Dec; 22(8):505-13. PubMed ID: 17902187
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder.
    Lasser RA, Bossie CA, Zhu Y, Gharabawi G, Eerdekens M, Davidson M.
    Int J Geriatr Psychiatry; 2004 Sep; 19(9):898-905. PubMed ID: 15352149
    [Abstract] [Full Text] [Related]

  • 11. Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: efficacy, quality of life and functional outcome.
    Lloyd K, Latif MA, Simpson S, Shrestha KL.
    Hum Psychopharmacol; 2010 Apr; 25(3):243-52. PubMed ID: 20373476
    [Abstract] [Full Text] [Related]

  • 12. Long-acting risperidone in young adults with early schizophrenia or schizoaffective illness.
    Lasser RA, Bossie CA, Zhu Y, Locklear JC, Kane JM.
    Ann Clin Psychiatry; 2007 Apr; 19(2):65-71. PubMed ID: 17612845
    [Abstract] [Full Text] [Related]

  • 13. A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea.
    Lee NY, Kim SH, Cho SJ, Chung YC, Jung IK, Kim CY, Kim DH, Lee DG, Lee YH, Lim WJ, Na YS, Shin SE, Woo JM, Yoon JS, Yoon BH, Ahn YM, Kim YS.
    Int Clin Psychopharmacol; 2014 Sep; 29(5):279-87. PubMed ID: 24583566
    [Abstract] [Full Text] [Related]

  • 14. Risperidone long-acting injection (RLAI): the 12-week efficacy and tolerability in Thai patients with chronic schizophrenia.
    Arunpongpaisal S, Srisurapanont M, Kongsakon R, Kitiwattanagul K, Samanwongthai U.
    J Med Assoc Thai; 2010 Mar; 93(3):343-50. PubMed ID: 20420110
    [Abstract] [Full Text] [Related]

  • 15. Safety and efficacy of long-acting injectable risperidone in daily practice: an open-label, noninterventional, prospective study in schizophrenia and related disorders.
    Parellada E, Kouniakis F, Siurkute A, Schreiner A, Don L.
    Int Clin Psychopharmacol; 2010 May; 25(3):149-54. PubMed ID: 20305567
    [Abstract] [Full Text] [Related]

  • 16. Does oral antipsychotic pre-treatment influence outcome of a switch to long-acting injectable risperidone in patients with schizophrenia?
    Schmauss M, Diekamp B, Gerwe M, Schreiner A, Ibach B.
    Pharmacopsychiatry; 2010 Mar; 43(2):73-80. PubMed ID: 20131207
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of risperidone long-acting injectable in stable psychotic patients previously treated with oral risperidone.
    Schmauss M, Sacchetti E, Kahn JP, Medori R.
    Int Clin Psychopharmacol; 2007 Mar; 22(2):85-92. PubMed ID: 17293708
    [Abstract] [Full Text] [Related]

  • 18. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.
    Li H, Rui Q, Ning X, Xu H, Gu N.
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun 01; 35(4):1002-8. PubMed ID: 21315787
    [Abstract] [Full Text] [Related]

  • 19. Improved symptom control, functioning and satisfaction in French patients treated with long-acting injectable risperidone.
    Llorca PM, Bouhours P, Moreau-Mallet V, French investigators group.
    Encephale; 2008 Apr 01; 34(2):170-8. PubMed ID: 18597725
    [Abstract] [Full Text] [Related]

  • 20. [Long-acting injectable risperidone: naturalistic study in three hospitals in Aquitaine].
    Raignoux C, Dusouchet T, Bret P, Queuille E, Biscay ML, Caron J, Bret MC.
    Encephale; 2007 Dec 01; 33(6):973-81. PubMed ID: 18789790
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.